by Peter Ciszewski | Dec 18, 2020
Thihan Padukkavidana, MD, from Takeda Oncology, discusses data on the efficacy and safety of ponatinib in chronic-phase chronic myeloid leukemia (CML) patients. This data was presented at ASH 2020. CML is a rare blood cancer characterized by the unregulated...
by Peter Ciszewski | Dec 18, 2020
Thierry Facon, MD, of Centre Hospitalier Universitaire (CHU) Lille, discusses the various treatment options for patients with multiple myeloma. Multiple myeloma is a rare blood cancer characterized by malignant plasma cell growth in the bone marrow. Stem...
by Peter Ciszewski | Dec 17, 2020
Anthony Mato, MD, from Memorial Sloan Kettering Cancer Center gives an overview of chronic lymphocytic leukemia (CLL) and discusses findings of the informCLL registry presented at ASH 2020. As Dr. Mato explains, CLL is a rare blood cancer resulting in a...
by Peter Ciszewski | Dec 16, 2020
Susan Samson, MD, PhD discusses a new treatment option for acromegaly. Mycapssa (octreotide) capsules are a long-term maintenance therapy for people with acromegaly. Mycapssa is the only oral form of octreotide, a somatostatin analog, approved by the US Food and Drug...
by Peter Ciszewski | Dec 16, 2020
James Dean, MD, Senior Medical Director at Pharmacyclics, discusses outcomes of a pooled analysis of 4 clinical trials of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) as well as outcomes of an integrated analysis of the RESONATE-2 and...
